Delivery Order SPE2DR25D1017-SPE2DR26F9DKM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,678.08 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) with an ultimate completion date of January 13, 2026. This non-set-aside, firm fixed-price delivery order was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $1,607.95 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply). This was a competitively awarded, firm fixed-price delivery order with no set-aside designation, completed on December 16, 2025, with an ultimate completion date of December 17, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a $19,458.59 delivery order to AmerisourceBergen Drug Corp on January 16, 2026, for the supply of Ondansetron ODT 4 mg tablets (30-count packages). The contract represents a firm fixed-price delivery order with an ultimate completion date of January 20, 2026, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made on a competitive basis with no set-aside designation. AmerisourceBergen Drug Corp, a subsidiary...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,739.72 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This firm fixed-price delivery order was awarded on January 9, 2026, with an ultimate completion date of January 12, 2026, and represents a non-set-aside competitive award. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The award is...
- The Defense Logistics Agency awarded a delivery order valued at $11,535.36 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of December 16, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in medical procurement for military and veteran healthcare systems. The delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,643.79 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This firm fixed-price delivery order, awarded on December 17, 2025, with an ultimate completion date of December 18, 2025, represents a routine pharmaceutical procurement under a competitive award with no set-aside designation. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,528.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in a 30-count package. The contract is a firm fixed price delivery order with an ultimate completion date of November 10, 2025, and was competitively awarded with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $1,144.14 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in a 30-count package, with an ultimate completion date of January 13, 2026. This competitive award, issued on January 12, 2026, utilizes firm fixed-price pricing and does not include a set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company operates as a...
- The Defense Logistics Agency awarded a $4,677.35 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count packages) on December 11, 2025, with a completion date of December 12, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a delivery order valued at $3,691.68 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count) on January 13, 2026. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of January 14, 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. The company is a subsidiary of Cencora, Inc.,...
- SPE2DR25D1017Indefinite Delivery Contract
- SPE2DR25D1017-SPE2DR26F9DKMDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,295.50 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This competitively awarded, firm fixed-price delivery order was issued on January 16, 2026, with an ultimate completion date of January 20, 2026. The pharmaceutical product will be performed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract under the parent entity Cencora, Inc. (formerly known as AmerisourceBergen), which provides comprehensive pharmaceutical and medical supply distribution services to federal government agencies. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2026. This prime vendor contract serves as a critical supply vehicle for military healthcare systems, enabling the delivery of a broad range of pharmaceutical products including specialty medications, brand-name and generic drugs, and medical supplies to support Defense Health Agency operations and other government healthcare systems worldwide. The supplier's extensive portfolio of federal contracts demonstrates its capability to meet stringent federal procurement requirements through open competition across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 1/15/26 |